Cargando…
Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
[Image: see text] Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in which P2′ residue Leu17 (bovine pancreatic trypsin inhibitor numbering) is mutated to Arg selectively inhibits the active site of plasmin with ∼5-fold improved affinity. Thrombin cleavage (24 h extended incubation at a 1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985851/ https://www.ncbi.nlm.nih.gov/pubmed/24383758 http://dx.doi.org/10.1021/bi401584b |
_version_ | 1782311635943161856 |
---|---|
author | Kumar, Yogesh Vadivel, Kanagasabai Schmidt, Amy E. Ogueli, Godwin I. Ponnuraj, Sathya M. Rannulu, Nalaka Loo, Joseph A. Bajaj, Madhu S. Bajaj, S. Paul |
author_facet | Kumar, Yogesh Vadivel, Kanagasabai Schmidt, Amy E. Ogueli, Godwin I. Ponnuraj, Sathya M. Rannulu, Nalaka Loo, Joseph A. Bajaj, Madhu S. Bajaj, S. Paul |
author_sort | Kumar, Yogesh |
collection | PubMed |
description | [Image: see text] Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in which P2′ residue Leu17 (bovine pancreatic trypsin inhibitor numbering) is mutated to Arg selectively inhibits the active site of plasmin with ∼5-fold improved affinity. Thrombin cleavage (24 h extended incubation at a 1:50 enzyme-to-substrate ratio) of the KD1 mutant (Leu17Arg) yielded a smaller molecule containing the intact Kunitz domain with no detectable change in the active-site inhibitory function. The N-terminal sequencing and MALDI-TOF/ESI data revealed that the starting molecule has a C-terminal valine (KD1(L17R)-V(T)), whereas the smaller molecule has a C-terminal lysine (KD1(L17R)-K(T)). Because KD1(L17R)-K(T) has C-terminal lysine, we examined whether it could serve as a decoy receptor for plasminogen/plasmin. Such a molecule might inhibit plasminogen activation as well as the active site of generated plasmin. In surface plasmon resonance experiments, tissue plasminogen activator (tPA) and Glu-plasminogen bound to KD1(L17R)-K(T) (K(d) ∼ 0.2 to 0.3 μM) but not to KD1(L17R)-V(T). Furthermore, KD1(L17R)-K(T) inhibited tPA-induced plasma clot fibrinolysis more efficiently than KD1(L17R)-V(T). Additionally, compared to ε-aminocaproic acid KD1(L17R)-K(T) was more effective in reducing blood loss in a mouse liver-laceration injury model, where the fibrinolytic system is activated. In further experiments, the micro(μ)-plasmin–KD1(L17R)-K(T) complex inhibited urokinase-induced plasminogen activation on phorbol-12-myristate-13-acetate-stimulated U937 monocyte-like cells, whereas the μ-plasmin–KD1(L17R)-V(T) complex failed to inhibit this process. In conclusion, KD1(L17R)-K(T) inhibits the active site of plasmin as well as acts as a decoy receptor for the kringle domain(s) of plasminogen/plasmin; hence, it limits both plasmin generation and activity. With its dual function, KD1(L17R)-K(T) could serve as a preferred agent for controlling plasminogen activation in pathological processes. |
format | Online Article Text |
id | pubmed-3985851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American
Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-39858512015-01-02 Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain Kumar, Yogesh Vadivel, Kanagasabai Schmidt, Amy E. Ogueli, Godwin I. Ponnuraj, Sathya M. Rannulu, Nalaka Loo, Joseph A. Bajaj, Madhu S. Bajaj, S. Paul Biochemistry [Image: see text] Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in which P2′ residue Leu17 (bovine pancreatic trypsin inhibitor numbering) is mutated to Arg selectively inhibits the active site of plasmin with ∼5-fold improved affinity. Thrombin cleavage (24 h extended incubation at a 1:50 enzyme-to-substrate ratio) of the KD1 mutant (Leu17Arg) yielded a smaller molecule containing the intact Kunitz domain with no detectable change in the active-site inhibitory function. The N-terminal sequencing and MALDI-TOF/ESI data revealed that the starting molecule has a C-terminal valine (KD1(L17R)-V(T)), whereas the smaller molecule has a C-terminal lysine (KD1(L17R)-K(T)). Because KD1(L17R)-K(T) has C-terminal lysine, we examined whether it could serve as a decoy receptor for plasminogen/plasmin. Such a molecule might inhibit plasminogen activation as well as the active site of generated plasmin. In surface plasmon resonance experiments, tissue plasminogen activator (tPA) and Glu-plasminogen bound to KD1(L17R)-K(T) (K(d) ∼ 0.2 to 0.3 μM) but not to KD1(L17R)-V(T). Furthermore, KD1(L17R)-K(T) inhibited tPA-induced plasma clot fibrinolysis more efficiently than KD1(L17R)-V(T). Additionally, compared to ε-aminocaproic acid KD1(L17R)-K(T) was more effective in reducing blood loss in a mouse liver-laceration injury model, where the fibrinolytic system is activated. In further experiments, the micro(μ)-plasmin–KD1(L17R)-K(T) complex inhibited urokinase-induced plasminogen activation on phorbol-12-myristate-13-acetate-stimulated U937 monocyte-like cells, whereas the μ-plasmin–KD1(L17R)-V(T) complex failed to inhibit this process. In conclusion, KD1(L17R)-K(T) inhibits the active site of plasmin as well as acts as a decoy receptor for the kringle domain(s) of plasminogen/plasmin; hence, it limits both plasmin generation and activity. With its dual function, KD1(L17R)-K(T) could serve as a preferred agent for controlling plasminogen activation in pathological processes. American Chemical Society 2014-01-02 2014-01-28 /pmc/articles/PMC3985851/ /pubmed/24383758 http://dx.doi.org/10.1021/bi401584b Text en Copyright © 2014 American Chemical Society |
spellingShingle | Kumar, Yogesh Vadivel, Kanagasabai Schmidt, Amy E. Ogueli, Godwin I. Ponnuraj, Sathya M. Rannulu, Nalaka Loo, Joseph A. Bajaj, Madhu S. Bajaj, S. Paul Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain |
title | Decoy Plasminogen Receptor Containing a Selective
Kunitz-Inhibitory Domain |
title_full | Decoy Plasminogen Receptor Containing a Selective
Kunitz-Inhibitory Domain |
title_fullStr | Decoy Plasminogen Receptor Containing a Selective
Kunitz-Inhibitory Domain |
title_full_unstemmed | Decoy Plasminogen Receptor Containing a Selective
Kunitz-Inhibitory Domain |
title_short | Decoy Plasminogen Receptor Containing a Selective
Kunitz-Inhibitory Domain |
title_sort | decoy plasminogen receptor containing a selective
kunitz-inhibitory domain |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985851/ https://www.ncbi.nlm.nih.gov/pubmed/24383758 http://dx.doi.org/10.1021/bi401584b |
work_keys_str_mv | AT kumaryogesh decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT vadivelkanagasabai decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT schmidtamye decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT ogueligodwini decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT ponnurajsathyam decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT rannulunalaka decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT loojosepha decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT bajajmadhus decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain AT bajajspaul decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain |